- Change to Roster Claims Information Entry in the Fiscal Intermediary Standard System Direct Data Entry
- Drugs and Biologicals - Coverage and Billing
- Medicare Part B Drug Coverage
- Covered Medicare Part B Drugs/Biologicals
- Self-Administered Drug Exclusion
- Medicare Part B General Billing
- Discarded Drugs/Wastage and JW, JZ Modifier
- Chemotherapy General Infusion Information
- Monoclonal Antibodies in Treatment of Alzheimer’s Disease - Medicare Advantage Plan Responsibility
- Reimbursement for Pre-exposure Prophylaxis Using Antiretroviral Therapy to Prevent Human Immunodeficiency Virus Infection
- Unlisted Codes for Drugs and Biologicals (J3490, J3590 and J9999)
- Compound Drugs
- Patient-Supplied or Free-of-Charge Drugs
- Prolonged Drug and Biological Infusions Using an External Pump
- Coding for Sinuva™ Claims
- Radiopharmaceutical Reimbursement
- Dermal Injections for Treatment of Facial Lipodystrophy Syndrome
- Factor VIII Billing
- Intravitreal Beovu (Brolucizumab-dbl) Billing
- Proper Billing for LEQVIO® HCPCS Code J1306
- Erythropoiesis Stimulating Agents: Clinical Indications and Coverage Criteria Overview
- Proper Billing for TEZSPIRE™ HCPCS Code J2356
- Proper Billing Units for HCPCS Code J7320
- Providers Performing Facet Joint Injections (CPT Code 64476)
- Skin Substitutes
- Vaccines
- Related Content
Intravitreal Beovu (Brolucizumab-dbl) Billing
National Government Services has seen multiple variations of billing from providers for Intravitreal Beovu. This job aid provides clarification and proper billing for this drug.
For Medicare billing purposes in Jurisdiction 6 and Jurisdiction K, the correct billing is HCPCS J3590. In addition to the HCPCS code, you would need to bill the appropriate dose of 6 mg. if it is being used for one eye or 12 mg. if both eyes are injected.
Billing J3590 RT and J3590 LT would also be acceptable for billing purposes of both eyes, each with six mg. Note: This information is for billing 2019 dates of service.
For 2020 dates of service there is a HCPCS code to use for billing, J0179. Information for billing this service in 2020 may be found is policy article A52451 Billing and Coding: Ranibizumab, Aflibercept and Brolucizumab-dbll and Faricimab-svoa. Please make sure to review the policy article for all coverage criteria.
Reviewed 3/26/2024